European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 147, Issue 1 , Pages 15-20 , November 2009

Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin

  • Werner Rath

      Affiliations

    • Corresponding Author InformationTel.: +49 241 80 80 884; fax: +49 241 80 82 711.

Received 12 March 2009 ,Revised 13 May 2009 ,Accepted 18 June 2009.

References 

  1. Prendiville W, Elbourne D, Chalmers I. The effects of routine oxytocic administration in the management of the third stage of labor: an overview of the evidence from controlled clinical trials. Br J Obstet Gynecol. 1988;95:3–16
  2. Rochat RW, Koonin LM, Atrash HK, Jewett JF the Maternal Mortality Collaborative. Maternal mortality in the United States: report from the Maternal Mortality Collaborative. Obstet Gynecol. 1988;72:91–97
  3. Li XF, Fortney JA, Kotelchuck M, Glover LH. The postpartum period: the key to maternal mortality. Int J Gynecol Obstet. 1996;54:1–10
  4. World Health Organization . Global estimates of maternal mortality for 1995: results of an in-depth review analysis and estimation strategy (statement). Geneva: World Health Organization; 2001;
  5. Bouwmeester FW, Boltc AC, van Geijn HP. Pharmacological and surgical therapy for primary postpartum haemorrhage. Curr Pharm Des. 2005;11:759–773
  6. Chong Y-S, Su L-L, Arulkumaran S. Current strategies for the prevention of postpartum haemorrhage in the third stage of labour. Curr Opin Obstet Gynecol. 2004;16:143–150
  7. Wedisinghe L, Macleod M, Murphy DJ. Use of oxytocin to prevent haemorrhage at caesarean section–a survey of practice in the United Kingdom. Eur J Obstet Gynecol Reprod Biol. 2008;137:27–30
  8. Ozumba BC, Ezegwui HU. Blood transfusion and caesarean section in a developing country. J Obstet Gynecol. 2006;26:746–748
  9. Ryden G, Sjoholm J. Half-life of oxytocin in blood of pregnant and non-pregnant women. Acta Endocrinol (Copenh). 1969;61:425–431
  10. Fabian M, Forsling M, Jones J. The clearance and antidiuretic potency of neurohypophysal hormones in man, and their plasma binding and stability. J Physiol. 1969;204:653–658
  11. Chard T, Boyd N, Forsling M. The development of a radioimmunoassay for oxytocin: the extraction of oxytocin from plasma, and its measurement during parturition in human and goat blood. J Endocrinol. 1970;48:223–234
  12. McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev; 2004 [Issue I. Art. No: CD000201].
  13. Liabsuetrakul T, Choobun T, Peeyanajarassri K, Islam QM. Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev; 2007 [Issue 2. Art. No: CD005456].
  14. Choy CM, Lau WC, Tam WH, Yuen PM. A randomized controlled trial of intramuscular syntometrine and intravenous oxytocin in the management of the third stage of labour. BJOG. 2002;109:173–177
  15. Dumoulin JG. A reappraisal of the use of ergometrine. J Obstet Gynecol. 1981;1:178–181
  16. Carey M. Adverse cardiovascular sequelae of ergometrine. Br J Obstet Gynecol. 1993;100:865
  17. Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for prevention of Postpartum haemorrhage. Cochrane Database Syst Rev; 2004 [Issue I. Art. No: CD000494].
  18. Villar J, Gülmezoglu AM, Hofmeyr GJ, Forna F. Systematic review of randomized controlled trials of misoprostol to prevent postpartum haemorrhage. Obstet Gynecol. 2002;100:1301–1312
  19. Chong YS, Chua S, Arulkumaran S. Severe hyperthermia following oral misoprostol in the immediate postpartum period. Obstet Gynecol. 1997;90:703–704
  20. Boucher M, Nimrod CA, Tawagi GF, Meeker TA, Rennicks White RE, Vann J. Comparison of carbetocin and oxytocin for the prevention of postpartum haemorrhage following vaginal delivery: a double-blind randomized trial. J Obstet Gynecol Can. 2004;26:481–488
  21. Leung SW, Ng PS, Wong WY, Cheung TH. A randomized trial of carbetocin versus syntometrine in the management of the third stage of labour. BJOG. 2006;113:1459–1464
  22. Ngan L, Keong W, Martins R. Carbetocin versus a combination of oxytocin and ergometrine in control of postpartum blood loss. Int J Gynecol Obstet. 2007;97:152–153
  23. Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database Syst Rev; 2007 [Issue 3. Art. No: CD005457].
  24. Atke A, Vilhardt H. Uterotonic activity and myometrial receptor affinity of I-deamino-I-carba-2-tyrosine (O-methyl)-oxytocin. Acta Endocrinol (Copenh). 1987;19:971–976
  25. Norström A, Andersson A, Vilhardt H. Contractile effect of oxytocin and I-deamino-l-carba-2-tyrosine (O-methyl)-oxytocin in myometrial tissue from non-pregnant and term pregnant women. Acta Endocrinol (Copenh). 1990;122:566–568
  26. Sweeney G, Holbrook AM, Levine M, et al. Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women. Curr Ther Res. 1990;47:520–540
  27. Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analogue in the postpartum uterus. Clin Pharmacol Ther. 1992;52:60–67
  28. van Dongen PW, Verbruggen MM, de Groot ANJA, van Roosmalen J, Sporken JMJ, Schulz M. Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. Eur J Obstet Gynecol Reprod Biol. 1998;77:181–187
  29. Boucher M, Horbay GLA, Griffin P, Deschamps Y, Desjardins C, Schulz M, et al. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing cesarean section. J Perinatol. 1998;18:202–207
  30. Dansereau J, Joshi AK, Helewa ME, et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol. 1999;180:670–676
  31. Barton SR, Jackson A. The safety and efficiency of carbetocin to control uterine bleeding following caesarean section. Prenat Neonatal Med. 1996;1:185
  32. Del Angel-Garcia G, Garcia-Contreras F, Constantino-Casas P, et al. Economic evaluation of carbetocine for the prevention of uterine atony in patients with risk factors in Mexico. Value Health. 2006;9(6):A254
  33. Ferring Pharmaceuticals: Global Pharmacovigilance. Periodic safety update report for carbetocin. 17 July 2006. On file at Ferring Pharmaceutical A/S, Copenhagen. Denmark.
  34. Silcox J, Schulz P, Horbay GLA, Wassenaar W. Transfer of carbetocin into human breast milk. Obstet Gynecol. 1993;82:456–459
  35. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo Simulation. A practical approach. Med Decis Making. 1985;5:157–177

PII: S0301-2115(09)00422-9

doi: 10.1016/j.ejogrb.2009.06.018

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 147, Issue 1 , Pages 15-20 , November 2009

Article Tools